CHAMPION-PHOENIX results indicate benefits of cangrelor, effect of access site during PCI

LONDON — In this video, Antonio Gutierrez, MD, of Brigham and Women's Hospital in Boston, discusses results from a sub-analysis of the CHAMPION-PHOENIX trial, which he presented at the European Society of Cardiology Congress.

The study evaluated the safety and efficacy of a regimen of P2Y12 inhibitor cangrelor (Kengreal, The Medicines Company) followed by clopidogrel compared with clopidogrel alone in patients who underwent PCI with transradial or transfemoral access. The researchers found that cangrelor reduced the incidence of a primary composite endpoint of death, MI, revascularization and stent thrombosis at 48 hours at both access sites.

Gutierrez also noted that patients who underwent PCI via the radial artery exhibited a 30% to 66% reduction in bleeding risk, with no difference according to the use of cangrelor vs. clopidogrel.

Source: www.healio.com